Patient Support Line 1-866-433-8000, Monday-Friday: 8:00 AM to 8:00 PM ET
KISQALI with an aromatase inhibitor is proven to help reduce the risk of recurrence*
In clinical studies, people taking KISQALI with an aromatase inhibitor, a type of hormone therapy, helped reduce their risk of their breast cancer coming back. KISQALI is proven effective in people diagnosed with HR+, HER2- stage 2 or 3 early breast cancer who are at a high risk of cancer coming back.
*At 3 years, 91% of people taking KISQALI with an aromatase inhibitor (AI) were cancer-free, compared with 88% of people taking an AI alone, a difference of 3%.
Leading cancer experts choose ribociclib (KISQALI®)
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), written by leading cancer experts, recommend ribociclib (KISQALI®) + an AI as an option for eligible patients with HR+, HER2- early breast cancer to help prevent cancer from coming back.
KISQALI is approved for people with HR+, HER2- stage 2 or 3 early breast cancer with a high risk of coming back.
Watch how Erika embraces change and takes more control of her treatment journey
When Erika learned her breast cancer could come back, she spoke with her doctor and said yes to KISQALI with an aromatase inhibitor.